Literature DB >> 1746520

A population-based evaluation of glaucoma screening: the Baltimore Eye Survey.

J M Tielsch1, J Katz, K Singh, H A Quigley, J D Gottsch, J Javitt, A Sommer.   

Abstract

The Baltimore Eye Survey was a population-based survey conducted from January 1985 to November 1988 among residents of east Baltimore, Maryland, who were 40 years of age or older. A total of 5,308 black subjects and white subjects received a comprehensive screening examination for glaucoma including tonometry, visual fields, stereoscopic fundus photography, and a detailed medical and ophthalmic history. Based on a definitive examination, a diagnosis of glaucoma of any type was made for 196 persons. Tonometry, cup:disc ratio, and narrowest neuroretinal rim width were evaluated for their ability to correctly classify subjects into diseased or nondiseased states. There were no cutoff values at which these variables provided a reasonable balance of sensitivity and specificity, separately or in combination. Logistic regression models were fit that included demographic and other risk factors. Sensitivities and specificities were calculated for varying cutoff levels on the distribution of predicted probabilities. There was no cutoff for which reasonable sensitivity and specificity were obtained. The authors conclude that the effectiveness of current techniques for glaucoma screening is limited.

Entities:  

Mesh:

Year:  1991        PMID: 1746520     DOI: 10.1093/oxfordjournals.aje.a116013

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  105 in total

Review 1.  A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma.

Authors:  N N Osborne; J Melena; G Chidlow; J P Wood
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

2.  Appraising evaluations of screening/diagnostic tests: the importance of the study populations.

Authors:  R Harper; D Henson; B C Reeves
Journal:  Br J Ophthalmol       Date:  2000-10       Impact factor: 4.638

Review 3.  Primary open angle glaucoma. The need for a consensus case definition.

Authors:  M Kroese; H Burton
Journal:  J Epidemiol Community Health       Date:  2003-09       Impact factor: 3.710

4.  Glaucoma in the Marfan syndrome.

Authors:  N J Izquierdo; E I Traboulsi; C Enger; I H Maumenee
Journal:  Trans Am Ophthalmol Soc       Date:  1992

Review 5.  Number of people with glaucoma worldwide.

Authors:  H A Quigley
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

Review 6.  Retinal imaging and image analysis.

Authors:  Michael D Abràmoff; Mona K Garvin; Milan Sonka
Journal:  IEEE Rev Biomed Eng       Date:  2010

7.  Dorsomedial/Perifornical hypothalamic stimulation increases intraocular pressure, intracranial pressure, and the translaminar pressure gradient.

Authors:  Brian C Samuels; Nathan M Hammes; Philip L Johnson; Anantha Shekhar; Stuart J McKinnon; R Rand Allingham
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-10-23       Impact factor: 4.799

8.  Results of the betaxolol versus placebo treatment trial in ocular hypertension.

Authors:  Deborah Kamal; David Garway-Heath; Simon Ruben; Fiona O'Sullivan; Catey Bunce; Anath Viswanathan; Wendy Franks; Roger Hitchings
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-02-19       Impact factor: 3.117

9.  Combining Frequency Doubling Technology Perimetry and Scanning Laser Polarimetry for Glaucoma Detection.

Authors:  Jean-Claude Mwanza; Joshua L Warren; Jessica T Hochberg; Donald L Budenz; Robert T Chang; Pradeep Y Ramulu
Journal:  J Glaucoma       Date:  2015 Oct-Nov       Impact factor: 2.503

Review 10.  Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.

Authors:  M Elizabeth Fini; Stephen G Schwartz; Xiaoyi Gao; Shinwu Jeong; Nitin Patel; Tatsuo Itakura; Marianne O Price; Francis W Price; Rohit Varma; W Daniel Stamer
Journal:  Prog Retin Eye Res       Date:  2016-09-22       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.